AI To End Cancer, Alzheimer's & Heart Disease? Big Tech's Promise Meets Pharma Scepticism
Claude creator Anthropic's CEO Dario Amodei recently said that, "Cancer, Alzheimer's, heart disease, mental illness, these will be relics of the past in, I think, less than a decade." These are widespread medical conditions that affect millions of people and their families, with several continuing to pose some of the biggest challenges to modern medicine. "I think if we do this right, we can…
Big Tech executives, such as Anthropic's CEO Dario Amodei, have made bold claims that artificial intelligence (AI) could eradicate cancer, Alzheimer's, heart disease, and mental illness within a decade. These conditions pose significant challenges to modern medicine, affecting millions of people worldwide. Amodei believes AI could revolutionize medical science by expediting biological research, pharmaceutical development, and the discovery of novel treatments.
Prominent figures in the technology industry, including Elon Musk and Demis Hassabis, Google's AI division head, have echoed similar sentiments. Hassabis envisions AI reducing the typical decade-long drug discovery process to just a few weeks. He has highlighted AlphaFold's success in predicting protein structures as evidence of AI's potential to accelerate scientific research.
However, the pharmaceutical industry has expressed skepticism towards these predictions. Experts argue that AI may not be able to deliver cures for complex conditions like cancer and Alzheimer's within the proposed timeframe. Jeff Leiden, executive chairman of Vertex Pharmaceuticals, dismissed these projections as "complete BS." He pointed out that despite evaluating around 50 AI firms tasked with analyzing 10,000 drug compounds, none had produced a viable drug independently.
The pharmaceutical experts emphasize that identifying a potential drug candidate is just the beginning of a lengthy process. Afterward, the molecule must undergo rigorous laboratory experiments, animal testing, human clinical trials, and regulatory assessments before it can be approved for medical use. These stages typically account for the 10-to-12-year drug development cycle. Thus, AI can streamline the initial discovery process but cannot bypass the essential scientific and regulatory requirements that follow.
Even with AI's potential to expedite drug discovery, no AI-designed drug has yet achieved full clinical adoption as of 2026.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
